Paratek Pharmaceuticals, Inc.
75 Park Plaza
4th Floor
Boston
Massachusetts
02116
United States
Tel: 617-807-6600
Fax: 617-275-0039
Website: http://www.paratekpharm.com/
Email: info@paratekpharma.com
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.
Board of Directors Michael F. Bigham Chairman of the Board and Chief Executive Officer
Evan Loh, MD Director and President, Chief Medical Officer
Thomas J. Dietz, Ph.D. Director
Timothy Franson, M.D., Director
Richard Lim Director
Kristine Peterson Director
Robert Radie Director
Jeffrey Stein, Ph.D. Director
Last Updated: 04-23-02
114 articles with Paratek Pharmaceuticals, Inc.
-
Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
10/25/2017
The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website.
-
Paratek Release: Phase III Optic Study Microbiology Data Demonstrate Omadacycline Has Potent In Vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
10/6/2017
-
Paratek Release: Consistent Efficacy And Safety Profile Observed In New Analyses Of OASIS-1 Phase III Study Of Omadacycline In Patients With Difficult To Treat Comorbid Conditions
10/6/2017
-
Paratek Release: Omadacycline Receives Qualified Infectious Disease Product Designation From FDA For An Additional Indication In Uncomplicated Urinary Tract Infection
9/21/2017
-
Paratek To Host Investor Day On October 17, 2017
9/20/2017
-
Paratek Announces Inducement Grants Inder NASDAQ Listing Rule 5635(c)(4)
9/5/2017
-
Boston's Paratek Heads to The Auction Block
8/24/2017
-
Paratek Pharma Reports Second Quarter 2017 Financial Results And Provides Clinical Update
8/2/2017
-
Paratek Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
8/1/2017
-
Paratek Pharma's Antibiotic Meets All Endpoints in Late-Stage Study
7/18/2017
-
New Microbiology Data Reinforce Activity Of Paratek Pharma’s Omadacycline Against Pathogens Of Importance In Respiratory, Skin And Urinary Tract Infections
6/5/2017
-
Paratek Pharma To Present New Data From Omadacycline Development Program At ASM Microbe 2017
5/24/2017
-
Paratek Pharma Announces Completion Of Enrollment For Oral-Only Omadacycline Phase III Skin Study, Top-Line Data Expected In Mid-July
5/8/2017
-
Paratek Pharma Reports First Quarter 2017 Financial Results And Provides Clinical Update
5/4/2017
-
Paratek Pharma To Report First Quarter 2017 Financial Results And Provide Update On Clinical Progress On May 4, 2017
4/26/2017
-
Zai Lab Acquires China Rights To Novel Antibiotic From Paratek Pharma
4/25/2017
-
Paratek Pharma Release: Omadacycline Concentrations Exceed Tigecycline Levels In Lungs And Epithelial Lining Fluid According To Pharmacokinetic/Pharmacodynamic (PK/PD) Data
4/25/2017
-
Paratek Pharma And Zai Lab Announce Collaboration, Development And License Agreement For Omadacycline In China
4/24/2017
-
New Microbiology Data From Paratek Pharma Show Omadacycline Effective Against Most Common Skin Infections And Pathogens, Including MRSA
4/24/2017
-
New Health Economics Studies Highlight The Potential For Paratek Pharma’ Omadacycline To Provide Cost-Savings Compared To Standard Of Care For The Treatment Of Patients With Acute Bacterial Skin And Skin Structure Infections
4/24/2017